Efficacy of antiandrogens in androgen receptor-positive triple-negative metastatic breast cancer: Real-life data.
Breast
; 73: 103667, 2024 Feb.
Article
em En
| MEDLINE
| ID: mdl-38160476
ABSTRACT
Antiandrogens (AA) have been tested in clinical trials in androgen receptor (AR) + triple-negative breast cancer (TNBC). We aim to assess the clinical benefit rate (CBR) of AA in real life. The primary end-point was CBR at 6 months. Twenty-four patients were assessable and received abiraterone acetate (62 %), enzalutamide (8 %) and bicalutamide (30 %). CBR at 6 months was 29 % (7/24) with 2 CR, 3 PR and 2 SD. Four patients had a clinical benefit >12 months. Real-life efficacy of AA use in metastatic AR + TNBC are in line with data from published trials.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias de Mama Triplo Negativas
/
Antagonistas de Androgênios
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article